JS Medical will be exhibiting the EMDA® drug delivery system at BAUS Brighton.
Latest data from Guy’s & St Thomas’ endorses intravesical sequential BCG/EMDA+MMC for HR-NMIBC
BAUS, EAU and NICE have suggested that hospitals switch to our EMDA®+Mitomycin-C treatment due to the worldwide shortage of BCG.
We are counting down to BAUS 2019 in Glasgow next week.
Physion has appointed JS Consulting as their strategic advisor for the GCC & Middle East regions.
Following the recommendation in January 2019 by NICE to use EMDA® in research programmes as a treatment for bladder cancer, JS Medical has taken steps to ensure there will be no change to our delivery schedules in coming months.
NICE has called for EMDA® to be used in research programmes as a treatment for bladder cancer.